XOSLULTI
Market cap7mUSD
Dec 23, Last price
2.44NOK
1D
-4.31%
1Q
34.07%
IPO
-92.31%
Name
Ultimovacs ASA
Chart & Performance
Profile
Ultimovacs ASA, a pharmaceutical company, develops immunotherapies for cancers. Its lead product candidate is UV1, a peptide-based vaccine that induces T cell response against the universal cancer antigen telomerase. The company was incorporated in 2011 and is headquartered in Oslo, Norway.
Valuation
Title NOK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
Income | |||||||||
Revenues | |||||||||
Cost of revenue | 126,602 | 107,069 | 104,499 | ||||||
Unusual Expense (Income) | |||||||||
NOPBT | (126,602) | (107,069) | (104,499) | ||||||
NOPBT Margin | |||||||||
Operating Taxes | (20,891) | 2,035 | |||||||
Tax Rate | |||||||||
NOPAT | (126,602) | (86,178) | (106,534) | ||||||
Net income | (189,239) 28.82% | (146,901) -11.91% | (166,757) 42.87% | ||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 300 | 5,484 | 272,864 | ||||||
BB yield | -0.01% | -0.15% | -7.47% | ||||||
Debt | |||||||||
Debt current | 1,827 | 1,767 | 1,628 | ||||||
Long-term debt | 5,599 | 9,193 | 2,542 | ||||||
Deferred revenue | |||||||||
Other long-term liabilities | (1,000) | ||||||||
Net debt | (259,133) | (414,349) | (569,998) | ||||||
Cash flow | |||||||||
Cash from operating activities | (189,827) | (167,695) | (125,828) | ||||||
CAPEX | (25) | (195) | (85) | ||||||
Cash from investing activities | 14,034 | 8,691 | 2,977 | ||||||
Cash from financing activities | (1,847) | 3,577 | 259,957 | ||||||
FCF | (124,613) | (89,680) | (104,690) | ||||||
Balance | |||||||||
Cash | 266,559 | 425,309 | 574,168 | ||||||
Long term investments | |||||||||
Excess cash | 266,559 | 425,309 | 574,168 | ||||||
Stockholders' equity | (797,216) | (626,957) | (477,689) | ||||||
Invested Capital | 1,080,320 | 1,081,788 | 1,072,926 | ||||||
ROIC | |||||||||
ROCE | |||||||||
EV | |||||||||
Common stock shares outstanding | 34,398 | 34,247 | 32,373 | ||||||
Price | 122.80 11.64% | 110.00 -2.48% | 112.80 41.00% | ||||||
Market cap | 4,224,074 12.13% | 3,767,170 3.16% | 3,651,674 50.85% | ||||||
EV | 3,964,941 | 3,352,821 | 3,081,676 | ||||||
EBITDA | (123,834) | (104,421) | (101,796) | ||||||
EV/EBITDA | |||||||||
Interest | 382 | 15,839 | 333 | ||||||
Interest/NOPBT |